Title:Drug Repurposing Using FDA Adverse Event Reporting System (FAERS)
Database
Volume: 25
Issue: 7
Author(s): Robert Morris, Rahinatu Ali and Feng Cheng*
Affiliation:
- Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL33612,
USA
- Department of Biostatistics and Epidemiology, College of Public Health, University of South Florida, Tampa,
FL33612, USA
Keywords:
FAERS, FDA, drug repurposing, LINCS, drug repositioning, connectivity mapping, CMAP, pharmacovigilance.
Abstract: Drug repurposing is an emerging approach to reassigning existing pre-approved therapies
for new indications. The FDA Adverse Event Reporting System (FAERS) is a large database
of over 28 million adverse event reports submitted by medical providers, patients, and drug manufacturers
and provides extensive drug safety signal data. In this review, four common drug repurposing
strategies using FAERS are described, including inverse signal detection for a single disease,
drug-drug interactions that mitigate a target ADE, identifying drug-ADE pairs with opposing
gene perturbation signatures and identifying drug-drug pairs with congruent gene perturbation signatures.
The purpose of this review is to provide an overview of these different approaches using
existing successful applications in the literature. With the fast expansion of adverse drug event reports,
FAERS-based drug repurposing represents a promising strategy for discovering new uses
for existing therapies.
